Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.
- 15 August 1991
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 88 (16) , 7175-7179
- https://doi.org/10.1073/pnas.88.16.7175
Abstract
Meningitis and other systemic infections caused by group B Neisseria meningitidis and Escherichia coli K1 remain important problems. The capsular polysaccharides (CPs) of these pathogens (poly[(2----8)-alpha-N-acetylneuraminic acid] or poly(alpha 2-8NeuNAc] are identical and are virulence factors and protective antigens for both. CP vaccines for these pathogens are not available because poly(alpha 2-8NeuNAc) alone, as a complex or a conjugate, is poorly immunogenic. Because oligomers of poly(alpha 2-8NeuNAc) in fetal brain and other tissues bind antibodies in vitro, it has been suggested that antibodies to this CP might be pathologic. We synthesized conjugates of this CP with tetanus toxoid under conditions that avoid lactone formation. Using this scheme, we also synthesized conjugates of group C meningococcal CP (poly[(2----9)-alpha-N-acetylneuraminic acid] or poly(alpha 2-9NeuNAc] and of E. coli K92 CP [poly(alpha 2-8, alpha 2-9NeuNAc)]. When injected s.c. in saline into mice, conjugates of poly(alpha 2-8NeuNAc) or poly(alpha 2-9NeuNAc) elicited homologous antibodies. E. coli K92 conjugates elicited both poly(alpha 2-8NeuNAc) and poly(alpha 2-9NeuNAc) antibodies. Both components of the conjugates expressed T-dependent immunologic properties under conditions and dosages acceptable for clinical evaluation. Poly(alpha 2-8NeuNAc) antibodies elicited by the homologous or the K92 conjugates had lower binding activities at 37 degrees C than at 22 degrees C. "Natural" poly(alpha 2-8NeuNAc) antibodies were present in almost all matched pairs of human maternal and cord sera; most cord levels were higher than in corresponding maternal sera. These findings suggest that increased levels of poly(alpha 2-8NeuNAc) IgG antibodies elicited by our conjugates will confer protective immunity to group B meningococci and E. coli K1 and will not be pathologic.Keywords
This publication has 43 references indexed in Scilit:
- Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteinsVaccine, 1991
- Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old childrenThe Journal of Pediatrics, 1988
- Human Monoclonal Antibody with Protective Activity for Escherichia coli K1 and Neisseria meningitidis Group B InfectionsThe Journal of Infectious Diseases, 1987
- MENINGOCOCCAL SEROTYPES AND SEROGROUP B DISEASE IN NORTH-WEST EUROPEThe Lancet, 1986
- A human monoclonal macroglobulin with specificity for alpha(2----8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA.The Journal of Experimental Medicine, 1986
- Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in ManJournal of Clinical Investigation, 1979
- Structural studies on the sialic acid polysaccharide antigen of Escherichia coli strain Bos-12Biochemistry, 1977
- Cross-Antigenicity and Immunogenicity between Capsular Polysaccharides of Group C Neisseria meningitidis and of Escherichia coli K92The Journal of Infectious Diseases, 1977
- RELATION BETWEEN ESCHERICHIA COLI K1 CAPSULAR POLYSACCHARIDE ANTIGEN AND CLINICAL OUTCOME IN NEONATAL MENINGITISThe Lancet, 1974
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969